Canagliflozin and cardiovascular outcomes in Type 2 diabetes

被引：2
|
作者：
Sarraju, Ashish [1 ,2 ]
Spencer-Bonilla, Gabriela [3 ]
Rodriguez, Fatima [1 ,2 ]
Mahaffey, Kenneth W. [1 ,2 ,4 ]
机构：
[1] Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Cardiovasc Inst, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA
[4] Stanford Ctr Clin Res, Stanford, CA 94304 USA
来源：
FUTURE CARDIOLOGY | 2020年 / 17卷 / 01期
基金：
美国国家卫生研究院;
关键词：
canagliflozin; cardiovascular disease; chronic kidney disease; nephropathy; SGLT2; sodium glucose; cotransporter; 2; inhibitors; Type; diabetes; HEART-DISEASE; CVD-REAL; EFFICACY; SAFETY; INHIBITORS; METFORMIN; RISK; GLIMEPIRIDE; FAILURE; PROFILE;
D O I：
10.2217/fca-2020-0029
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SGLT2 inhibitors have risen to prominence in recent years as Type 2 diabetes mellitus medications with favorable effects on cardiovascular (CV) and renal outcomes. Canagliflozin is a US FDA-approved SGLT2 inhibitor that has demonstrated CV and renal outcome benefits in large scale placebo-controlled randomized trials of patients with Type 2 diabetes mellitus and elevated CV risk. Canagliflozin use may also be associated with serious and nonserious adverse effects requiring ongoing monitoring in patients initiated on this medication. This paper provides a detailed overview of canagliflozin including its pharmacologic profile, clinical efficacy and safety data, with discussion of both clinical trial results, as well as real-world evidence.
引用
下载
收藏
页码：39 / 48
页数：10
相关论文
共 50 条
  • [21] Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    Wiviott, S. D.
    Raz, I.
    Bonaca, M. P.
    Mosenzon, O.
    Kato, E. T.
    Cahn, A.
    Silverman, M. G.
    Zelniker, T. A.
    Kuder, J. F.
    Murphy, S. A.
    Bhatt, D. L.
    Leiter, L. A.
    McGuire, D. K.
    Wilding, J. P. H.
    Ruff, C. T.
    Gause-Nilsson, I. A. M.
    Fredriksson, M.
    Johansson, P. A.
    Langkilde, A-M.
    Sabatine, M. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (04): : 347 - 357
  • [22] Empagliflozin and cardiovascular outcomes in type 2 diabetes
    Gregory B. Lim
    Nature Reviews Cardiology, 2016, 13 (1) : 3 - 3
  • [23] Thiazolidinediones and cardiovascular outcomes in type 2 diabetes
    Grant, P. J.
    HEART, 2009, 95 (04) : 332 - 332
  • [24] Consistent Outcomes with Canagliflozin (CANA) in Patients with Type 2 Diabetes across Geographic Regions-Results from the CANagliflozin CardioVascular Assessment Study (CANVAS) Program
    Wysham, Carol H.
    Bhattacharyya, Arpandev
    Tsoukas, Michael
    Martinez-Abundis, Esperanza
    Slee, April
    Shaw, Wayne
    Mahaffey, Kenneth W.
    de Zeeuw, Dick
    DIABETES, 2018, 67
  • [25] Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Marso, Steven P.
    Daniels, Gilbert H.
    Brown-Frandsen, Kirstine
    Kristensen, Peter
    Mann, Johannes F. E.
    Nauck, Michael A.
    Nissen, Steven E.
    Pocock, Stuart
    Poulter, Neil R.
    Ravn, Lasse S.
    Steinberg, William M.
    Stockner, Mette
    Zinman, Bernard
    Bergenstal, Richard M.
    Buse, John B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 311 - 322
  • [26] Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
    Cannon, Christopher P.
    Pratley, Richard
    Dagogo-Jack, Samuel
    Mancuso, James
    Huyck, Susan
    Masiukiewicz, Urszula
    Charbonnel, Bernard
    Frederich, Robert
    Gallo, Silvina
    Cosentino, Francesco
    Shih, Weichung J.
    Gantz, Ira
    Terra, Steven G.
    Cherney, David Z. I.
    McGuire, Darren K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15): : 1425 - 1435
  • [27] Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
    Baglioni, Piero
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (19): : 1880 - 1881
  • [28] MODELLING CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES IN THE ERA OF CARDIOVASCULAR OUTCOMES TRIALS
    McEwan, P.
    Chubb, B.
    Bennett, H.
    VALUE IN HEALTH, 2017, 20 (09) : A747 - A747
  • [29] Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: data from the CANVAS Program and CREDENCE
    Seufert, J.
    Woo, V.
    Tsoukas, M. A.
    Tobe, S. W.
    Slee, A.
    Rapattoni, W.
    Ang, F. G.
    Wheeler, D. C.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S280 - S281
  • [30] Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE
    Tsoukas, Michael A. A.
    Woo, Vincent
    Tobe, Sheldon W. W.
    Slee, April
    Rapattoni, Wally
    Ang, Fernando G. G.
    Seufert, Jochen
    Neuen, Brendon L. L.
    Arnott, Clare
    Mahaffey, Kenneth W. W.
    Wheeler, David C. C.
    DIABETES OBESITY & METABOLISM, 2023, 25 (07): : 2038 - 2042
12345